Shahidi and colleagues developed a synergistic approach by combining doxorubicin (DOX), a first-line chemotherapeutic agent, with silibinin, a natural compound, aiming to enhance the efficacy of HER2-positive breast cancer treatment while mitigating treatment-related toxicity [152]. The gene discussed is ERBB2; the disease is breast cancer.